Get the Stockscreener App
3.44
0.58%
-0.02
Larimar Therapeutics Inc stock is traded at $3.44, with a volume of 1.16M.
It is down -0.58% in the last 24 hours and up +19.44% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$3.46
Open:
$3.515
24h Volume:
1.16M
Relative Volume:
0.91
Market Cap:
$220.26M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-4.0952
EPS:
-0.84
Net Cash Flow:
$-33.46M
1W Performance:
-11.34%
1M Performance:
+19.44%
6M Performance:
-10.42%
1Y Performance:
-58.65%
1-Day Range:
$3.40
$3.5499
1-Week Range:
$3.27
$3.91
52-Week Range:
$1.61
$9.50
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.44 | 221.54M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
How does Larimar Therapeutics Inc. compare to its industry peersBreakout Stocks Tracker With High Returns - jammulinksnews.com
What are the technical indicators suggesting about Larimar Therapeutics Inc.Real Time Alerts For Fast Growth - jammulinksnews.com
Larimar Therapeutics raises $69 million in public offering By Investing.com - Investing.com India
Why Larimar Therapeutics Inc. is moving todayAutomated AI Forecast with Trading Alerts - Newser
Relative strength of Larimar Therapeutics Inc. in sector analysisSmart Trade Mapping with Entry Details - Newser
Analyzing recovery setups for Larimar Therapeutics Inc. investorsOversold Reversal Picks with Buy Zone - Newser
Short interest data insights for Larimar Therapeutics Inc.Free Real-Time Market Sentiment Tracking Tool - Newser
Larimar Therapeutics Announces Closing of Underwritten - GlobeNewswire
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares | LRMR Stock News - GuruFocus
Larimar Therapeutics Closes $69 Million Public Offering of Common Stock to Support Development of Pipeline Candidates - Quiver Quantitative
Rare Disease Biotech Larimar Secures $69M Windfall as Investors Rush to Oversubscribed Stock Offering - Stock Titan
Larimar Therapeutics Announces $64.4 Million Stock Offering - TipRanks
Using R and stats models for Larimar Therapeutics Inc. forecastingShort-Term AI-Based Stock Price Forecast - Newser
What recovery options are there for Larimar Therapeutics Inc.Free High Win Rate Trading Opportunities - Newser
What indicators show strength in Larimar Therapeutics Inc.Predictive System for Long-Term Stock Forecast - Newser
Is it time to cut losses on Larimar Therapeutics Inc.Conservative Entry for High Return Setup Backed - metal.it
Is Larimar Therapeutics Inc. stock overhyped or has real potentialFree Trade Setups With AI Powered Filters - Newser
Will Larimar Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
Larimar Therapeutics stock falls after $60 million public offering By Investing.com - Investing.com Canada
Multi asset correlation models including Larimar Therapeutics Inc.Free Breakout Momentum Picks With Protection - Newser
Larimar Therapeutics Inc. Stock Support and Resistance Levels You Should KnowIntelligent Trade Forecast With AI Analytics - Newser
LRMR Stock Priced at Lower End of Predetermined Range - GuruFocus
What makes Larimar Therapeutics Inc. stock price move sharplyTechnical Trade Plan with Entry Checklist - Newser
Striking the Balance: Larimar Therapeutics' $60M Raise and the Road to Nomlabofusp Approval - AInvest
Larimar Therapeutics Announces Pricing of Underwritten Public Offering | LRMR Stock News - GuruFocus
Larimar Therapeutics prices public offering at $3.20 per share - Investing.com
Larimar Therapeutics, Inc. Announces Pricing of $60 Million Public Offering of Common Stock - Quiver Quantitative
$60M Public Offering: How Larimar Therapeutics Plans to Advance Rare Disease Treatments - Stock Titan
Larimar Therapeutics Announces Pricing of Underwritten Public Offering - Yahoo Finance
Larimar Therapeutics Announces Pricing of Underwritten Public Offering - GlobeNewswire Inc.
Larimar Therapeutics Inc. Crosses 200 Day MA — Signal or NoiseLow Risk Equity Screener With Results Shared - metal.it
Larimar Therapeutics (LRMR) Launches Public Offering to Boost Development Efforts - GuruFocus
Form 424B5 Larimar Therapeutics, - StreetInsider
Larimar Therapeutics launches public offering of common stock By Investing.com - Investing.com Nigeria
Larimar Therapeutics Announces Proposed Underwritten Public Offering | LRMR Stock News - GuruFocus
Larimar Therapeutics launches public offering of common stock - Investing.com Australia
Larimar Therapeutics Announces Proposed Underwritten Public Offering - GlobeNewswire
Rare Disease Biotech Larimar Therapeutics Unveils Strategic Public Offering for Breakthrough Drug Development - Stock Titan
Larimar Therapeutics Inc. Consolidation Zone May Signal AccumulationSecure Return Focused Investment Plan Released - metal.it
Larimar Therapeutics Inc. Trading Near Value Zone — Recovery AheadCommunity Shared Smart Money Signals Show Movement - metal.it
How to escape a deep drawdown in Larimar Therapeutics Inc.Free Smart Trade Plans With Risk Protection - Newser
Larimar Therapeutics Bets Big On Rare Disease Breakthrough - Finimize
What are Larimar Therapeutics Inc. company’s key revenue driversPost Market Opportunities With High Returns - jammulinksnews.com
What is Larimar Therapeutics Inc. company’s growth strategyProven strategies for superior portfolio growth - jammulinksnews.com
Why is Larimar Therapeutics Inc. stock attracting strong analyst attentionBuild wealth faster with disciplined trading - jammulinksnews.com
Should I hold or sell Larimar Therapeutics Inc. stock in 2025Consistently outstanding ROI - jammulinksnews.com
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):